This article reviews the systematic review and meta-analysis by Trevis et al. comparing long-term outcomes after aortic valve replacement (AVR) with mechanical versus bioprosthetic valves in patients aged 50 to 70 years.

The expansion of transcatheter aortic valve implantation avoids open surgery, but also prevents concomitant repair of associated tricuspid regurgitation. This study assesses the consequences of leaving this second valve untreated and seeks to identify which patient profiles might benefit most from conventional combined surgery.

Single-centre retrospective propensity score–matched study from Columbia University Irving Medical Center, New York, comparing double valve surgery (DVS) with isolated transcatheter aortic valve replacement (I-TAVR) in patients with severe aortic stenosis and concomitant moderate-to-severe mitral stenosis, with particular focus on heart failure readmissions during follow-up.

Translational study assessing the feasibility of percutaneous implantation of an aortic bioprosthesis within a dysfunctional mechanical valve (ViMech-TAVI), from an animal model to the first-in-human cases.

This article, published in February 2026, provides a concise update on the evaluation and management of tricuspid regurgitation (TR), in light of the major advances in both the diagnostic assessment of tricuspid valve disease and the emergence of new evidence on surgical and transcatheter treatment.

Case series study with 1-year follow-up on tricuspid valve replacement using the patient’s native right atrial appendage instead of an artificial prosthesis.

Analysis of several surgical videos on transatrial implantation of balloon-expandable prostheses in severe MAC. The essential procedural steps are reviewed, and technical pearls based on the author’s own experience are shared.

Subanalysis of the PROMOTE study assessing the incidence and clinical impact of prophylactic permanent pacemaker implantation for conduction disturbances after TAVR.

This study analyzes the Mayo Clinic experience comparing 2 cohorts of patients with degenerative mitral valve (MV) disease undergoing repair, with and without obstructive hypertrophic cardiomyopathy (oHCM), the latter treated with concomitant septal myectomy.